Did the company provide revised guidance for upcoming quarters or FY 2025?

Answer to the question

Based on the release, BrainStorm Cell Therapeutics (BCLI) only announced its second‑quarter 2025 financial results and a corporate update. The filing does not mention a revision to its guidance for the remainder of the year or for FY 2025, so there is no updated earnings outlook to factor into the market at this time.

Trading implications

• Fundamentals: With Q2 2025 results now public, the market will focus on the disclosed revenue, cash‑burn, and any new clinical‑trial milestones. Until the company explicitly revises its forward‑looking guidance, analysts will continue to model the prior FY 2025 expectations (e.g., the pre‑release consensus of modest revenue growth and continued R&D expense).
  
• Technical: BCLI has been trading in a relatively tight range ahead of the earnings call, reflecting the “wait‑and‑see” stance of investors. In the absence of a guidance shift, the stock is likely to remain range‑bound in the short term, with upside potential only if the Q2 results beat expectations on a top‑line or cash‑flow basis. A breakout above the recent resistance around $1.20 could trigger a short‑term rally, while a breach below the $1.00 support level may signal renewed weakness.
  
• Actionable insight: Keep the position flat or lightly long on the back of the Q2 results, but do not commit to a directional bet until the company issues a formal guidance update (e.g., in a Q3 or year‑end release). Monitor the call transcript for any subtle hints of future revenue or expense trends that could foreshadow a guidance revision, and be ready to adjust exposure if management signals a change in FY 2025 outlook.